Boxer Capital Management, LLC
SAN DIEGO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.15B2026 Q3
Positions47
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.71.4%
What Changed This Quarter?
Top Holdings
TNGX
Tango Therapeutics
22.8%
KOD
Kodiak Sciences
12.2%
RVMD
Revolution Medicines
8.9%
KYMR
Kymera Therapeutics
5.1%
REPL
Replimune
4.9%
ABVX
Abivax S.A.
4.1%
SRZN
Surrozen
3.8%
CORT
Corcept Therapeutics
3.4%
New / Increased
12 new · 9 increased
ACHVNEW
Achieve Life Science
1.5%
CCCCNEW
C4 Therapeutics
1.2%
TRAXNEW
First Tracks Biotherapeutics
0.7%
SABSNEW
SAB Biotherapeutics
0.7%
CGEMNEW
Cullinan Therapeutics
0.6%
SYRE
Spyre Therapeutics
2.2%
+183.1%
KYMR
Kymera Therapeutics
5.1%
+22.2%
IRD
Opus Genetics
1.9%
+61.1%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.